Skip to main content
Erschienen in: Journal of Neurology 4/2019

28.01.2019 | Original Communication

Cognitive changes of older adults with an equivocal amyloid load

verfasst von: Kristell Pothier, Laure Saint-Aubert, Claudie Hooper, Julien Delrieu, Pierre Payoux, Philipe de Souto Barreto, Bruno Vellas, MAPT/DSA Study Group

Erschienen in: Journal of Neurology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Observational and interventional studies addressing the link between amyloid (Aβ) burden and cognitive decline are increasing, but a clear definition of amyloid positivity is still lacking. This may represent a great stake for therapeutic studies enrolling Aβ + patients only. The main objective of this study was to define a population with “equivocal” amyloid status, and evaluate their cognitive changes.

Methods

Sixty-five participants over 75 years old, from the Control group of the interventional MAPT study, at risk to develop Alzheimer’s disease, were included. Participants were classified into three groups in terms of amyloid load: Aβ +, Aβ − and Equivocal participants (according to visual reading, global standardized uptake (SUVR) cut-offs, or a k-mean clustering method). The cognitive changes over time (memory, executive functions, attention and processing speed) of this Equivocal group were then compared to Aβ + and Aβ − participants.

Results

When classified by visual read, Equivocal participants’ memory scores were comparable to the Aβ- participants, and greater than in Aβ + participants over time. Secondary analyses, using SUVR cut-offs classification, showed different trajectories with Equivocal participants being comparable to the Aβ + participants, and lower than Aβ-, on executive performance over time.

Conclusions

This original work pointed out a population that may be of great interest for interventional studies, raising the question of how amyloid status should be defined and integrated in such studies. These findings should be replicated in future studies on larger datasets, to confirm what methodological approach would be the most suitable to highlight this specific neuroimaging entity.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Herholz K, Ebmeier K (2011) Clinical amyloid imaging in Alzheimer’s disease. Lancet Neurol 10(7):667–670CrossRefPubMed Herholz K, Ebmeier K (2011) Clinical amyloid imaging in Alzheimer’s disease. Lancet Neurol 10(7):667–670CrossRefPubMed
2.
Zurück zum Zitat Ma Y, Zhang S, Li J, Zheng DM, Guo Y, Feng J, Ren WD (2014) Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. Medicine 93:27 Ma Y, Zhang S, Li J, Zheng DM, Guo Y, Feng J, Ren WD (2014) Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. Medicine 93:27
3.
Zurück zum Zitat Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, … Park DC (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. J Alzheimer’s Assoc 7(3):280–292CrossRef Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, … Park DC (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. J Alzheimer’s Assoc 7(3):280–292CrossRef
5.
Zurück zum Zitat Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, Maruff P (2017) Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alzheimer’s Dement 6:108–121 Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, Maruff P (2017) Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alzheimer’s Dement 6:108–121
7.
Zurück zum Zitat Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, … Smith C (2007) Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med 48(4):547–552CrossRefPubMed Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, … Smith C (2007) Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med 48(4):547–552CrossRefPubMed
8.
Zurück zum Zitat Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Doraiswamy PM (2011) Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 68(11):1404–1411CrossRefPubMed Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Doraiswamy PM (2011) Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 68(11):1404–1411CrossRefPubMed
9.
Zurück zum Zitat Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Jagust WJ (2012) Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annal Neurol 72(4):578–586CrossRefPubMed Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Jagust WJ (2012) Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annal Neurol 72(4):578–586CrossRefPubMed
10.
Zurück zum Zitat Camus V, Payoux P, Barré L, Desgranges B, Voisin T, Tauber C, Mondon K (2012) Using PET with 18 F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 39(4):621–631CrossRefPubMedPubMedCentral Camus V, Payoux P, Barré L, Desgranges B, Voisin T, Tauber C, Mondon K (2012) Using PET with 18 F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 39(4):621–631CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, Saha K (2012) Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects. J Nucl Med 53(3):378–384CrossRefPubMed Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, Saha K (2012) Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects. J Nucl Med 53(3):378–384CrossRefPubMed
12.
Zurück zum Zitat Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Eriksson J, Nordberg A (2016) Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm. Eur J Nucl Med Mol Imag 43(9):1686–1699CrossRef Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Eriksson J, Nordberg A (2016) Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm. Eur J Nucl Med Mol Imag 43(9):1686–1699CrossRef
13.
Zurück zum Zitat Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, Jagust WJ (2012) Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage 59(2):1152–1160CrossRefPubMed Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, Jagust WJ (2012) Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage 59(2):1152–1160CrossRefPubMed
14.
Zurück zum Zitat Payoux P, Delrieu J, Gallini A, Adel D, Salabert AS, Hitzel A, Fernandez P (2015) Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings. Eur J Nucl Med Mol Imag 42(9):1459–1468CrossRef Payoux P, Delrieu J, Gallini A, Adel D, Salabert AS, Hitzel A, Fernandez P (2015) Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings. Eur J Nucl Med Mol Imag 42(9):1459–1468CrossRef
15.
Zurück zum Zitat Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, Bories L (2014) MAPT study: a multidomain approach for preventing Alzheimer’s disease: design and baseline data. J Prevent Alzheimer’s Dis 1(1):13 Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, Bories L (2014) MAPT study: a multidomain approach for preventing Alzheimer’s disease: design and baseline data. J Prevent Alzheimer’s Dis 1(1):13
16.
Zurück zum Zitat Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, Desclaux F (2017) Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 16(5):377–389CrossRefPubMed Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, Desclaux F (2017) Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 16(5):377–389CrossRefPubMed
17.
Zurück zum Zitat Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ, Jagust W (2017) In vivo staging of regional amyloid deposition. Neurology 89(20):2031–2038CrossRefPubMedPubMedCentral Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ, Jagust W (2017) In vivo staging of regional amyloid deposition. Neurology 89(20):2031–2038CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Hedden T, Oh H, Younger AP, Patel TA (2013) Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology 80(14):1341–1348CrossRefPubMedPubMedCentral Hedden T, Oh H, Younger AP, Patel TA (2013) Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology 80(14):1341–1348CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Landau SM, Horng A, Jagust WJ, Alzheimer’s Disease Neuroimaging Initiative (2018) Memory decline accompanies subthreshold amyloid accumulation. Neurology 5:10–1212 Landau SM, Horng A, Jagust WJ, Alzheimer’s Disease Neuroimaging Initiative (2018) Memory decline accompanies subthreshold amyloid accumulation. Neurology 5:10–1212
20.
Zurück zum Zitat Kemppainen N, Johansson J, Teuho J, Parkkola R, Joutsa J, Ngandu T, Paajanen T (2018) Brain amyloid load and its associations with cognition and vascular risk factors in FINGER Study. Neurology 90(3):e206–e213CrossRefPubMed Kemppainen N, Johansson J, Teuho J, Parkkola R, Joutsa J, Ngandu T, Paajanen T (2018) Brain amyloid load and its associations with cognition and vascular risk factors in FINGER Study. Neurology 90(3):e206–e213CrossRefPubMed
21.
Zurück zum Zitat Cohen AD, Mowrey W, Weissfeld LA, Aizenstein HJ, McDade E, Mountz JM, Williamson J (2013) Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage 71:207–215CrossRefPubMed Cohen AD, Mowrey W, Weissfeld LA, Aizenstein HJ, McDade E, Mountz JM, Williamson J (2013) Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage 71:207–215CrossRefPubMed
22.
Zurück zum Zitat Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, Rowe CC (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s Dement 11(1):1–15CrossRef Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, Rowe CC (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s Dement 11(1):1–15CrossRef
23.
Zurück zum Zitat Farrell ME, Kennedy KM, Rodrigue KM, Wig G, Bischof GN, Rieck JR, Park DC (2017) Association of longitudinal cognitive decline with amyloid burden in middle-aged and older adults: evidence for a dose-response relationship. JAMA Neurol 74(7):830–838CrossRefPubMedPubMedCentral Farrell ME, Kennedy KM, Rodrigue KM, Wig G, Bischof GN, Rieck JR, Park DC (2017) Association of longitudinal cognitive decline with amyloid burden in middle-aged and older adults: evidence for a dose-response relationship. JAMA Neurol 74(7):830–838CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Chételat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Rowe CC (2012) Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 78(7):477–484CrossRefPubMed Chételat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Rowe CC (2012) Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 78(7):477–484CrossRefPubMed
Metadaten
Titel
Cognitive changes of older adults with an equivocal amyloid load
verfasst von
Kristell Pothier
Laure Saint-Aubert
Claudie Hooper
Julien Delrieu
Pierre Payoux
Philipe de Souto Barreto
Bruno Vellas
MAPT/DSA Study Group
Publikationsdatum
28.01.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 4/2019
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-019-09203-5

Weitere Artikel der Ausgabe 4/2019

Journal of Neurology 4/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

03.05.2024 Parkinson-Krankheit Nachrichten

Kann eine frühzeitige Stuhltransplantation das Fortschreiten von Parkinson-Symptomen verlangsamen? Die Ergebnisse einer randomisierten Phase-2-Studie scheinen dafür zu sprechen.

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

02.05.2024 Hirnblutung Nachrichten

Erhalten Personen mit einer spontanen Hirnblutung innerhalb von zwei Stunden nach Symptombeginn eine Tranexamsäure-Therapie, kann dies weder die Hämatomexpansion eindämmen noch die Mortalität senken.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.